Financing ·
Pulse Biosciences entered into a new equity distribution agreement with Mizuho Securities USA LLC on September 15…
PLSEPulse Biosciences, Inc.
Pulse Biosciences entered into a new equity distribution agreement with Mizuho Securities USA LLC on September 15, 2026, establishing an at-the-market offering program allowing the sale of up to $85 million in common stock. The company terminated its prior at-the-market offering program with TD Cowen, under which approximately $1.0 million remained unsold as of the termination date. This new agreement supplements an existing August 2026 Mizuho program, through which the company has already sold shares totaling approximately $68.8 million. Pulse Biosciences operates in the medical device industry, developing electroporation technologies for cancer treatment.